Menu
Recruiting NCT06338280

Remotely Observed Methadone Evaluation II

Phase II Interventional Opioid Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sonara.
Who it may be relevant to
Registry conditions: Opioid Use Disorder. Basic parameters: 18 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Remote Observed Methadone Evaluation Phase II (ROME II): Retention and Costs of Care

Overview

Methadone is an effective treatment for severe opioid use disorder (OUD), but access is limited due to the requirement of daily observed dosing by most opioid treatment programs (OTPs). Sonara Health designed a HIPAA-compliant web-application called Sonara that features integrated video dosing recording, a tamper-evident seal, and an innovative measurement-based care (MBC) framework called the Opioid Craving Visual Analogue Scale (OC-VAS) to facilitate methadone take-homes while providing evidence of appropriate use and monitoring patient outcomes. Phase II of this SBIR aims to compare Sonara against usual take-homes to assess its impact on retention in care, opioid use, patient outcomes, and costs of care.

Interventions

  • Other Sonara
    Sonara virtual dosing window and engagement platform

Primary outcome measures

  • Retention [Time frame: 24 weeks]
  • Take homes received over time [Time frame: 24 weeks]
Secondary outcome measures (5)
  • Opioid cravings [Time frame: 24 weeks]
  • Urine toxicology [Time frame: 24 weeks]
  • Opioid withdrawal severity [Time frame: 24 weeks]
  • Health-related quality of life [Time frame: 24 weeks]
  • Drug Abuse Treatment Costs Analysis [Time frame: 24 weeks]

Eligibility criteria

Inclusion criteria

  • Willing to participate in a randomized trial
  • Able to complete study instruments and interviews

Exclusion criteria

  • Less than 18 years of age
  • Pregnant or planning to be pregnant
  • Currently involved in the criminal justice system
  • Serious mental health problems
  • Treated with buprenorphine

Please note: The enrollment target (2.5 randomizations per week over 50 weeks) includes oversampling women and under-represented racial/ethnicity groups (i.e., at least 10 or more individuals per group who identify as Black, Hispanic, and American Indian/Alaskan Native).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • FGC Wabash — Chicago

Identifiers

NCT: NCT06338280 · VDW002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗